AstraZeneca PLC

詳細情報 AstraZeneca PLC 企業名

AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.

企業情報

企業コードAZN

会社名AstraZeneca PLC

上場日Sep 21, 2007

設立日1992

最高経営責任者「CEO」Mr. Marc Dunoyer

従業員数94300

証券種類Ordinary Share

決算期末Sep 21

本社所在地1 Francis Crick Avenue

都市CAMBRIDGE

証券取引所London Stock Exchange

国United Kingdom

郵便番号CB2 0AA

電話番号442073045000

ウェブサイトhttps://www.astrazeneca.com/

企業コードAZN

上場日Sep 21, 2007

設立日1992

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Ms. Susan Galbraith

Executive Vice President - Oncology and Research and Development

--

Mr. Marc Dunoyer

Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca

--

Mr. David (Dave) Fredrickson

Executive Vice President - Oncology Business Unit

--

Mr. Pascal Soriot

Chief Executive Officer, Executive Director

--

Mr. Philip Broadley

Senior Non-Executive Independent Director

--

Dr. Ruud Dobber, Ph.D.

Executive Vice President - BioPharmaceuticals Business Unit

--

Ms. Diana Layfield

Non-Executive Independent Director

--

Mr. Rene Haas

Non-Executive Director

--

Mr. Michel Demare

Non-Executive Independent Chairman of the Board

--

Ms. Aradhana Sarin, M.D.

Chief Financial Officer, Executive Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Ms. Susan Galbraith

Executive Vice President - Oncology and Research and Development

--

Mr. Marc Dunoyer

Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca

--

Mr. David (Dave) Fredrickson

Executive Vice President - Oncology Business Unit

--

Mr. Pascal Soriot

Chief Executive Officer, Executive Director

--

Mr. Philip Broadley

Senior Non-Executive Independent Director

--

Dr. Ruud Dobber, Ph.D.

Executive Vice President - BioPharmaceuticals Business Unit

--

収益内訳

通貨: USD更新時刻: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

Farxiga

7.66B

15.03%

Tagrisso

6.58B

12.92%

Imfinzi

4.72B

9.26%

Ultomiris

3.92B

7.70%

Calquenc

3.13B

6.14%

Other

24.93B

48.95%

地域別USD

会社名

収益

比率

United States

21.81B

42.81%

China

6.42B

12.60%

United Kingdom

4.74B

9.31%

Other European Countries

3.66B

7.19%

Japan

3.45B

6.78%

Other

10.86B

21.32%

事業別

地域別

事業別USD

会社名

収益

比率

Farxiga

7.66B

15.03%

Tagrisso

6.58B

12.92%

Imfinzi

4.72B

9.26%

Ultomiris

3.92B

7.70%

Calquenc

3.13B

6.14%

Other

24.93B

48.95%

株主

更新時刻: Sat, May 24

株主統計

種類

株主統計

比率

PRIMECAP Management Company

1.31%

Wellington Management Company, LLP

1.15%

Capital International Investors

1.01%

T. Rowe Price Associates, Inc.

0.96%

T. Rowe Price International Ltd

0.88%

Other

94.69%

株主統計

比率

PRIMECAP Management Company

1.31%

Wellington Management Company, LLP

1.15%

Capital International Investors

1.01%

T. Rowe Price Associates, Inc.

0.96%

T. Rowe Price International Ltd

0.88%

Other

94.69%

種類

株主統計

比率

Investment Advisor

9.35%

Investment Advisor/Hedge Fund

5.99%

Research Firm

0.89%

Hedge Fund

0.64%

Bank and Trust

0.16%

Pension Fund

0.03%

Family Office

0.02%

Family Office

0.02%

Family Office

0.02%

Other

82.89%

機関投資家保有株

更新時刻: Sun, Jan 19

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q1

2003

543.18M

17.51%

-2.86M

2024Q4

1985

546.17M

17.61%

+11.21M

2024Q3

1920

519.95M

16.76%

-17.37M

2024Q2

1910

530.80M

17.12%

-10.51M

2024Q1

1865

523.00M

16.86%

-21.20M

2023Q4

1838

520.78M

16.79%

-27.28M

2023Q3

1815

530.17M

17.10%

-14.80M

2023Q2

1812

525.36M

16.94%

-28.74M

2023Q1

1803

534.31M

17.23%

-35.06M

2022Q4

1806

550.27M

17.75%

-33.14M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

PRIMECAP Management Company

41.02M

1.32%

-960.52K

-2.29%

Dec 31, 2024

Wellington Management Company, LLP

37.04M

1.19%

-208.20K

-0.56%

Dec 31, 2024

Capital International Investors

37.51M

1.21%

+686.01K

+1.86%

Dec 31, 2024

T. Rowe Price Associates, Inc.

33.74M

1.09%

-3.07M

-8.34%

Dec 31, 2024

T. Rowe Price International Ltd

26.61M

0.86%

+530.22K

+2.03%

Dec 31, 2024

Managed Account Advisors LLC

16.43M

0.53%

-1.13M

-6.44%

Dec 31, 2024

Fisher Investments

10.96M

0.35%

+479.69K

+4.58%

Dec 31, 2024

Fidelity Management & Research Company LLC

18.15M

0.59%

-1.10M

-5.70%

Dec 31, 2024

Sanders Capital, LLC

15.19M

0.49%

+212.30K

+1.42%

Dec 31, 2024

Putnam Investment Management, L.L.C.

11.80M

0.38%

+1.29M

+12.23%

Dec 31, 2024

詳細を見る

関連ETF

更新時刻: Thu, Jun 5

銘柄名

比率

First Trust WCM International Equity ETF

5.52%

Invesco Nasdaq Biotechnology ETF

4.42%

Parnassus Value Select ETF

4.35%

ProShares Ultra Nasdaq Biotechnology

4.2%

VanEck Pharmaceutical ETF

4.14%

Invesco QQQ Low Volatility ETF

4.06%

Amplify Weight Loss Drug & Treatment ETF

4.04%

Roundhill GLP-1 & Weight Loss ETF

3.44%

Franklin Income Focus ETF

3.39%

Franklin Genomic Advancements ETF

3.05%

詳細を見る

First Trust WCM International Equity ETF

比率5.52%

Invesco Nasdaq Biotechnology ETF

比率4.42%

Parnassus Value Select ETF

比率4.35%

ProShares Ultra Nasdaq Biotechnology

比率4.2%

VanEck Pharmaceutical ETF

比率4.14%

Invesco QQQ Low Volatility ETF

比率4.06%

Amplify Weight Loss Drug & Treatment ETF

比率4.04%

Roundhill GLP-1 & Weight Loss ETF

比率3.44%

Franklin Income Focus ETF

比率3.39%

Franklin Genomic Advancements ETF

比率3.05%

配当金

過去5年間の配当金総支払額は 20.90B 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

Feb 06, 2025

AZN.NB Interim Cash Dividend of gross USD 1.05 paid on Mar 24, 2025 going ex on Feb 21, 2025

Feb 21, 2025

Mar 24, 2025

Feb 21, 2025

Jul 25, 2024

AZN.NB Final Cash Dividend of gross USD 0.5 paid on Sep 09, 2024 going ex on Aug 09, 2024

Aug 09, 2024

Sep 09, 2024

Aug 09, 2024

Feb 08, 2024

AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 25, 2024 going ex on Feb 22, 2024

Feb 23, 2024

Mar 25, 2024

Feb 22, 2024

Jul 28, 2023

AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 11, 2023 going ex on Aug 10, 2023

Aug 11, 2023

Sep 11, 2023

Aug 10, 2023

Feb 10, 2023

AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 27, 2023 going ex on Feb 23, 2023

Feb 24, 2023

Mar 27, 2023

Feb 23, 2023

Aug 01, 2022

AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 12, 2022 going ex on Aug 11, 2022

Aug 12, 2022

Sep 12, 2022

Aug 11, 2022

Feb 10, 2022

AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 28, 2022 going ex on Feb 24, 2022

Feb 25, 2022

Mar 28, 2022

Feb 24, 2022

Aug 02, 2021

AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 13, 2021 going ex on Aug 12, 2021

Aug 13, 2021

Sep 13, 2021

Aug 12, 2021

Feb 11, 2021

AZN.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2021 going ex on Feb 25, 2021

Feb 26, 2021

Mar 29, 2021

Feb 25, 2021

Jul 30, 2020

AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 14, 2020 going ex on Aug 13, 2020

Aug 14, 2020

Sep 14, 2020

Aug 13, 2020

詳細を見る

株式分割

日付

種類

比率

データなし

日付

種類

比率

データなし

69.680USD

AstraZeneca PLC

69.680

概要

企業名